About Pharmion
Pharmion is a Healthcare company based in Boulder (United States) founded in 2000, and was acquired by Celgene in November 2007. Therapies for the treatment of hematology and oncology disorders. Pharmion has raised $40 million across 2 funding rounds from investors including General Electric, Nomura and Celgene. Pharmion has completed 1 acquisition, including Cabrellis Pharmaceuticals. Its focus areas include Diversified Pharmaceuticals.
Company details
Pharmion was established in 2000 in Boulder, United States, within the pharmaceutical sector. Operations centered on the acquisition, development, and commercialization of products targeting hematology and oncology disorders. Key offerings included Vidaza, an approved epigenetic cancer drug; Thalidomide Pharmion for multiple myeloma; Innohep, an antithrombotic agent; and Refludan, a thrombin inhibitor. The company was acquired by Celgene in November 2007 for 2.9 billion.
- Headquarters Boulder, United States
- Stage Acquired
- SectorsHealthcare
- Website pharmion.com
- Social LinkedIn
- Acquired by Celgene (Nov 2007)
- Total Equity Funding$40M (USD)
in 2 rounds
- Latest Funding Round$40M (USD), Series A
Oct 2002
- InvestorsGeneral Electric
& 11 more
- Investments & Acquisitions
- Acquired byCelgene
(Nov 2007)
Funding Insights of Pharmion
Pharmion has successfully raised a total of $40M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $40 million completed in October 2002. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $40M
- Total Rounds 2
- Last Round Series A — $40M
- First Round $65M
(Dec 2001)
- Investors Count 11
All 2 funding rounds of Pharmion with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2002 | $40M | Series A | – | – | |
| Dec 2001 | $65M | Debt – Conventional | – | – |
12 investors in total: 12 institutional.
Investors in Pharmion
Pharmion has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include General Electric, Nomura and Celgene.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
| proquestvc.com | ||||
Stage-agnostic investments in US life-sciences sectors are managed. | baycitycapital.com | San Francisco, United States | ||
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
Stage-agnostic life sciences-focused VC firm investing in North America & Europe | neomed.net | Oslo, Norway | ||
| healthcap.eu | ||||
Life science & tech focused VC firm investing in the US | domainvc.com | Princeton, United States | ||
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
| merlinnexus.com | ||||
Diversified operations are conducted across multiple industries worldwide. | 1892 | ge.com | United States |
Investor details for Pharmion
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Pharmion
Pharmion has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Cabrellis Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Small molecule therapeutics for cancer treatment are developed. | cabrellis.com | Summit, United States | 1986 | Nov 2006 | $59M |
Complete acquisition details for Pharmion
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Pharmion
6 dated milestones of Pharmion across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Pharmion is founded.
- Funding First funding round of $65.0M.
- Funding Latest funding round, Series A, of $40.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Cabrellis Pharmaceuticals.
- Exit Acquired by Celgene.
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Pharmion (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 5.33 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pharmion
Complete news archive for Pharmion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pharmion
Pharmion was founded in 2000 and raised its 1st funding round 1 year after it was founded.
Pharmion is headquartered in Boulder, United States. It is registered at Boulder, Colorado, United States.
Pharmion is a funded company, having raised a total of $40M across 2 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $65M, raised on Dec 2001.
Pharmion was established in 2000 in Boulder, United States, within the pharmaceutical sector. Operations centered on the acquisition, development, and commercialization of products targeting hematology and oncology disorders. Key offerings included Vidaza, an approved epigenetic cancer drug; Thalidomide Pharmion for multiple myeloma; Innohep, an antithrombotic agent; and Refludan, a thrombin inhibitor. The company was acquired by Celgene in November 2007 for 2.9 billion.
Pharmion has made 1 acquisition, including Cabrellis Pharmaceuticals.
Pharmion has 12 investors. Key investors include General Electric, Nomura, Celgene, Abingworth, and NEA.
Yes. Pharmion was acquired by Celgene in November 2007.